Zifo

Come and join us and many industry peers in Basel on June the 2nd!

There is a unique professional fulfillment that comes from having a great conversation that turns into a meaningful story. I hope you enjoy reading it as much as I enjoyed the chat that sparked it!

Excited to be attending Bio-IT World 2026 this May! It’s always a great opportunity to connect with the community advancing AI, data, and innovation in life sciences. If you are attending and like to meet up, send me a message. Also come visit the Zifo booth on the exhibit floor and learn about how Zifo can help you modernize your data and lab informatics landscape! #BioITExpo #Biotech #DataScience #Innovation More: https://lnkd.in/g2Vp8CZi

Just one week to go! Don't miss the chance to join our complementary Lunch & Learn Hamburg event to learn practical ways to implement AI and network with R&D colleagues. Register here: https://lnkd.in/egC3JX2i #AI #digitaltransformation #Data #digitalinnovation #labinformatics #zifo

Lab assay data lives in 47 different Excel files across shared drives and researchers' laptops. Most of us recognize this isn't sustainable. The pressures converging in 2026 are making this increasingly difficult to justify. Spreadsheets persist for understandable reasons: flexibility, familiarity, perceived speed, and frankly, because clunky LIMS deployments from years past left scars. Many scientists would rather deal with version control nightmares than repeat that implementation trauma. The hidden costs are real. Scientists waste hours searching for specific assay runs from six months ago. Experiments get duplicated because a team member left and took institutional knowledge with them. Cross-study comparisons become impossible. Version control disasters accumulate (you've probably encountered " results_final_FINAL_v3_USE_THIS.xlsx " at some point). And there's no audit trail when regulatory inquiries arrive. What's shifting the calculation now: - AI/ML initiatives require standardized, integrated training data that disconnected spreadsheets cannot provide - Regulatory scrutiny around data provenance and integrity is increasing, with auditors asking questions spreadsheets cannot answer - Remote and distributed teams make shared drive coordination increasingly fragile - Competitors are using historical data systematically for discovery - Executive pressure for R&D ROI demonstration demands data that can actually be analyzed across studies Modern LIMS/ELN platforms have evolved significantly from those painful implementations of the past. Cloud-based systems designed around actual laboratory workflows, automated instrument integration, mobile accessibility, and native connections to analytical tools. Platforms from vendors like Sapio, Benchling, and LabVantage now incorporate AI capabilities for experiment planning, anomaly detection, and compliance checking. Spreadsheets have always had technical limitations for this use case. What's changed is whether the pain of continuing finally exceeds the pain of changing. With AI expectations and regulatory pressure converging, that calculation has shifted. Implementation requires genuine IT-lab leadership partnership. Technology selection matters less than how you manage the organizational change. Rollouts must be phased. Scientists need to see how the system helps their work, not just satisfies institutional requirements. At Zifo, we help organizations implement modern AI-driven LIMS/ELN that address both technical requirements and change management realities. The foundation you build now determines whether AI initiatives deliver value or remain theoretical. Curious to hear how others are approaching this transition. #datastrategy #lifesciences #laboratoryinformatics

🚀 Datadog Summit Bengaluru 2026 — more practical than I expected. I went in with the intention of just understanding Datadog better as a monitoring platform. But what stood out was how much the focus has shifted from just observing systems to actually acting on them in real time. One of the most interesting parts for me was the #AWSGameDaySpeedRun . Worked on a live troubleshooting challenge using Bits AI SRE, where the goal wasn’t just to identify issues, but to move faster towards resolution with AI assistance. It felt closer to real production scenarios than typical demos. A few things that stayed with me: • Observability is no longer passive — it's becoming decision-making + execution • The gap between detecting an issue and fixing it is shrinking with AI-driven workflows • Performance conversations are now tightly tied to actual user behavior, not just system metrics • Even small frontend delays (like a button click) can directly impact user retention The sessions by Namit D'Cruz , Michael Whetten, Abrar Hussain , Divya Gupta Arora , and Nimish Chaudhary all connected back to one theme: 👉 systems are getting more complex, but the expectation for speed and reliability is only increasing. A standout idea was from Abrar Hussain’s session — using Private Action Runner + AI agents to trigger automated fixes within the environment itself. Another moment that stuck with me was Nimish Chaudhary’s journey — from a Java developer to Chief Technology & Product Owner at Wow! Momo. It was a reminder that growth in tech isn’t just about tools, but about continuously evolving with the ecosystem. Overall, this wasn’t just about tools — it was about how engineering workflows are evolving with AI in the loop. Definitely changed how I think about monitoring and incident handling. #DatadogSummit #Observability #SRE #DevOps #AWS #AI #SystemDesign #Performance

Coefficient Bio had fewer than ten employees when Anthropic paid $400 million for it in April 2026. Anthropic was buying proprietary biological training data and the systematic capability to generate more of it. GSK committed $50 million to NOETIK. Eli Lilly signed with Chai Discovery. The common thread across these early 2026 deals: companies that built biology-native data infrastructure from inception, rather than bolting AI onto legacy systems after the fact. The valuation premium is shifting in ways that life sciences data leaders need to pay attention to: - The intersection of biological expertise and data architecture now commands premium valuations. Organizations that produce well-structured, standardized data AI models can actually consume are the ones attracting partnership interest. - Computational power is abundant. Proprietary biological training data that can't be scraped from the internet remains scarce. - Most organizations possess decades of valuable biological insights. Much of it sits trapped in siloed LIMS and ELN systems designed primarily for compliance documentation. - Companies commanding partnership premiums invested early in FAIR principles, standardized ontologies (aligned with initiatives like Allotrope Foundation and Pistoia Alliance), integrated laboratory informatics, and API-first architectures. - Data network effects from these partnerships are creating barriers that late movers will struggle to overcome. Can potential partners consume your biological data today, or is it locked in proprietary formats that require months of remediation? Consider whether your data infrastructure would add value in a partnership discussion or create friction. Organizations that treated data architecture as a cost center are discovering it may determine their strategic positioning in a market that only values computable data. At Zifo , we help life sciences organizations assess whether their data infrastructure positions them for these opportunities. The window for building AI-ready foundations is narrowing. #datastrategy #aiready #lifesciences

I’m pleased to share that I had the opportunity to present a poster titled “Shaping Our Submission Journey with D-Pack” for the m5 submission package at PharmaSUG SDE 2026, held at Eli Lilly and company Bangalore. The conference offered valuable insights into how AI will shape the future of statistical programming. The panel discussion at the end was particularly engaging and truly made the conference worthwhile to attend. It was great to be part of this experience with my colleague Priyadharshini Rajasekaran . I would like to sincerely thank Albin Praveen Kumar , Soundharavalli Sekar , Ebence Golda and Sreelekha Pasupuleti for their constant support, and Zifo for providing this opportunity. # PharmaSUG # Eli Lilly and Company

It’s always interesting to peel back the PR layers and get to the heart of the matter -- questions like whether something genuinely counts as “AI,” or whether a new hypothesis deserves to be called a “discovery.” I enjoy talking with our Chief Scientist about these things. They might sound like semantics at first, but with so much PR noise out there, having grounded conversations like this feels refreshing and necessary.